Combo of RAF/MEK Inhibitor and Defactinib Shows Promise in Patients With KRAS+ Ovarian Cancer

In an interview with Oncology Learning Network, Udai Banerji, MD, NIHR Professor of Molecular Cancer Pharmacology, The Institute of Cancer Research, London, United Kingdom, discussed the findings and clinical significance of a phase 1 trial evaluating the use of VS-6766, a RAF/MEK inhibitor, plus defactinib, a FAK inhibitor, in patients with KRAS-mutant ovarian cancer.